GLAND - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | GLAND | Market Cap | 26,330 Cr. | Current Price | 1,597 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 22.2 | Book Value | 610 ₹ | Dividend Yield | 1.13 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,742 ₹ | DMA 200 | 1,776 ₹ |
| Chg in FII Hold | -0.32 % | Chg in DII Hold | 0.36 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 33.1 | MACD | -47.5 | Volume | 39,366 | Avg Vol 1Wk | 94,466 |
| Low price | 1,200 ₹ | High price | 2,131 ₹ | PEG Ratio | -6.47 | Debt to equity | 0.00 |
| 52w Index | 42.6 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 27.2 |
📊 Analysis: Gland Pharma shows moderate efficiency with ROCE at 15.8% and ROE at 11.6%. The company is debt-free, which adds financial stability. Valuation-wise, the P/E of 22.2 is below the industry average of 27.2, suggesting fair pricing. However, the PEG ratio of -6.47 indicates weak growth prospects relative to valuation. Dividend yield of 1.13% provides modest income support. Technical indicators (RSI 33.1, MACD -47.5) show oversold conditions, with the stock trading below both DMA 50 and DMA 200, signaling bearish momentum.
💰 Entry Price Zone: Considering current weakness and oversold RSI, the ideal entry zone is ₹1,450–₹1,550, closer to support levels and below DMA 200 (₹1,776). This range offers better risk-reward compared to current levels.
📈 Exit / Holding Strategy: For long-term investors, Gland Pharma’s moderate ROE/ROCE and fair valuation justify cautious holding for 2–4 years. Exit strategy should involve profit booking near ₹1,950–₹2,050 if valuations expand. Dividend yield supports holding, but monitor growth metrics and institutional activity (recent FII decline) for signals of weakness.
✅ Positive
- Debt-free balance sheet ensures financial safety.
- P/E of 22.2 is lower than industry average (27.2).
- Quarterly PAT growth of 10.4% shows earnings momentum.
- Dividend yield of 1.13% adds stability.
⚠️ Limitation
- PEG ratio of -6.47 indicates poor growth prospects.
- ROE (11.6%) and ROCE (15.8%) are moderate.
- Stock trading below DMA 50 and DMA 200 indicates weak trend.
📉 Company Negative News
- Decline in FII holdings (-0.32%).
- Stock corrected from 52-week high of ₹2,131 to near ₹1,597.
📈 Company Positive News
- Quarterly PAT improved from ₹302 Cr. to ₹326 Cr.
- DII holdings increased (+0.36%), showing domestic confidence.
- EPS of ₹71 reflects steady profitability.
🏭 Industry
- Pharmaceutical sector benefits from global demand and regulatory approvals.
- Industry PE of 27.2 reflects moderate optimism in the sector.
📝 Conclusion
Gland Pharma is financially stable with fair valuation but faces growth challenges as reflected in its negative PEG ratio. Ideal entry is around ₹1,450–₹1,550. Long-term investors can hold for 2–4 years, supported by dividend yield and moderate profitability, with partial profit booking near ₹1,950–₹2,050 if valuations expand.